Global Market Report

Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030

Our 180+ page report provides 100+ tables, charts, and graphs. Read on to discover the most key areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Novel Coronavirus (COVID-19) Drugs in Development Market. See how to exploit the opportunities.

SKU: PHA0732 Category: Tags: , , , , , , , , Code: PHA0732Pages: 180
Clear
← Back to category Therapeutic Drugs

Description

** Subsidised Report Price**

As you know, Visiongain is a business information provider. One of our key aims is to help business grow – your business. It is also part of our remit to serve the companies that use us. We may not be able to develop a vaccine, but we can try and help the companies that do. And we will do that, by doing what we do – informing your industry.

So please register NOW to receive your FREE, business information guide to the current and future market of vaccines being designed for COVID-19. If this report can help you and your organisation structure a potential drug, business case, or regional targeting of resources etc – then please let us know. This is all we can do, to help you do what your company does.

Our 150+ page report provides 100+ tables, charts, and graphs. Read on to discover the most key areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Novel Coronavirus Drugs in Development Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the global market and submarkets

Along with revenue prediction for the overall world market, there are 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional level.

Global Novel Coronavirus (COVID-19) Drugs in Development Market by Drugs

• Remdesivir
• Chloroquine and hydroxychloroquine
• Ritonavir/lopinavir
• Ritonavir/lopinavir + interferon beta
• Others

Global Novel Coronavirus (COVID-19) Drugs in Development Market by Age Group

• <10 Years
• 10-19 Years
• 20-29 Years
• 30-80 Years
• >80 Years

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

North America: U.S., Canada

Europe: Germany, France, UK, Italy, Spain, Rest of Europe

Asia-Pacific: Japan, China, India, Taiwan, South Korea, Rest of Asia-Pacific

Rest of the World

The report also includes profiles and for some of the leading companies in the Novel Coronavirus (COVID-19) Drugs in Development Market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that both developed and developing markets, U.S., UK, Germany, Italy, India and China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth

Visiongain predict strong revenue growth through to 2030 for Novel Coronavirus (COVID-19) Drugs.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Novel Coronavirus (COVID-19) Drugs in Development Market report helps you

In summary, our 180+ page report provides you with the following knowledge:

• Revenue forecasts to 2030 for 2 segmentations, 5 Drugs, 5 Age Groups, each forecasted at a global and regional level. Discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2030 for 4 regional and 12 key national markets. See forecasts for the Novel Coronavirus (COVID-19) Drugs in Development market in North America, Europe, Asia-Pacific and Rest of the World.

• Prospects for established firms and those seeking to enter the market. Including company profiles for 10 of the major companies involved in the Novel Coronavirus (COVID-19) Drugs in Development Market

• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain study is for everybody needing commercial analyses for the Novel Coronavirus (COVID-19) Drugs in Development market and leading companies. You will find data, trends and predictions.

Get our report today COVID-19 Drugs Development Market Analysis: Revenue Prospects by Type (Remdesivir, Chloroquine and Hydroxychloroquine, Ritonavir/Lopinavir, Ritonavir/Lopinavir + Interferon Beta, Others), Age Group (<10 Years, 10-19 Years, 20-29 Years, 30-80 Years, >80 Years) and Geography. Avoid missing out by staying informed , order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with?

Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help.

1. Report Overview
1.1 Global Novel Coronavirus (COVID-19) Drugs in Development Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Includes
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction
2.1 Objectives of the Study
2.2 Market Definition
2.3 Market Scope
2.4 Markets Covered
2.5 Years Considered for the Study
2.6 Limitations
2.7 Currency

3. Industry Insights
3.1 Market Drivers
3.1.1 Sudden rise in death rates amongst major economies across the globe
3.1.2 Pandemic situation caused due to the virus outbreak
3.1.3 Unavailability of vaccine for COVID-19
3.2 Market Restraints/Challenges
3.2.1 Regulatory Scenario
3.2.2 Lack of awareness in developing economies
3.2.3 Inadequate information regarding the virus and its mechanism
3.3 Market Opportunities
3.3.1 Growing Economies
3.3.2 Rising disposable income couple with growing healthcare expenditure
3.3.3 Unaffected countries with large geriatric population
3.4 Global Outbreak Landscape by Country
3.4.1 China
3.4.2 U.S.
3.4.3 Italy
3.4.4 UK
3.4.5 Germany
3.4.6 India
3.4.7 Netherlands
3.4.8 Other Countries
3.5 Political Outlook by Country
3.5.1 U.S.
3.5.2 Germany
3.5.3 UK
3.5.4 France
3.5.5 Italy
3.5.6 Netherlands
3.5.7 China
3.5.8 India
3.5.9 Other Countries
3.6 World Population Prospects
3.6.1 By Age Group
3.7 Health Expenditure (Major Economies)
3.7.1 U.S.
3.7.2 Canada
3.7.3 Germany
3.7.4 UK
3.7.5 France
3.7.6 Italy
3.7.7 Spain
3.7.8 Netherlands
3.7.9 Japan
3.7.10 China
3.7.11 India
3.7.12 South Korea
3.7.13 Brazil
3.7.14 Mexico
3.8 GDP by Country
3.8.1 U.S.
3.8.2 Germany
3.8.3 Japan
3.8.4 China
3.8.5 India
3.8.6 UK
3.8.7 France
3.8.8 Italy
3.8.9 Brazil
3.8.10 Canada
3.8.11 Russia
3.8.12 South Korea
3.8.13 Spain
3.8.14 Australia
3.8.15 Mexico
3.8.16 Switzerland

4. Clinical Trials Landscape
4.1 Clinical Trial Activity by Major Companies/Research Firms

5. Novel Coronavirus (COVID-19) Drugs in Development Market - By Drugs
5.1 Remdesivir
5.1.1 Market size and forecast, 2020-2030 (US$ Million)
5.2 Chloroquine and hydroxychloroquine
5.2.1 Market size and forecast, 2020-2030 (US$ Million)
5.3 Ritonavir/lopinavir
5.3.1 Market size and forecast, 2020-2030 (US$ Million)
5.4 Ritonavir/lopinavir + interferon beta
5.4.1 Market size and forecast, 2020-2030 (US$ Million)

6. Novel Coronavirus (COVID-19) Drugs in Development Market - By Age Group
6.1 80 Years
6.5.1 Market size and forecast, 2020-2030 (US$ Million)

7. By Region
7.1 Introduction
7.2 North America Novel Coronavirus (COVID-19) Drugs in Development, 2020-2030 (US$ Million)
7.2.1 North America COVID-19 Market by Drugs, 2020-2030 (US$ Million)
7.2.2 North America COVID-19 Market by Age Group, 2020-2030 (US$ Million)
7.2.3 North America COVID-19 Market by Country, 2020-2030 (US$ Million)
7.2.3.1 U.S.
7.2.3.2 Canada
7.3 Europe Novel Coronavirus (COVID-19) Drugs in Development, 2020-2030 (US$ Million)
7.3.1 Europe COVID-19 Market by Drugs, 2020-2030 (US$ Million)
7.3.2 Europe COVID-19 Market by Age Group, 2020-2030 (US$ Million)
7.3.3 Europe COVID-19 Market by Country, 2020-2030 (US$ Million)
7.3.3.1 Germany
7.3.3.2 France
7.3.3.3 UK
7.3.3.4 Italy
7.3.3.5 Spain
7.3.3.6 Rest of Europe
7.4 Asia-Pacific Novel Coronavirus (COVID-19) Drugs in Development, 2020-2030 (US$ Million)
7.4.1 Asia Pacific COVID-19 Market by Drugs, 2020-2030 (US$ Million)
7.4.2 Asia Pacific COVID-19 Market by Age Group, 2020-2030 (US$ Million)
7.4.3 Asia Pacific COVID-19 Market by Country, 2020-2030 (US$ Million)
7.4.3.1 Japan
7.4.3.2 China
7.4.3.3 India
7.4.3.4 Taiwan
7.4.3.5 South Korea
7.4.3.6 Rest of Asia Pacific
7.5 Rest of the World Novel Coronavirus (COVID-19) Drugs in Development, 2020-2030 (US$ Million)
7.5.1 RoW COVID-19 Market by Drugs, 2020-2030 (US$ Million)
7.5.2 RoW COVID-19 Market by Age Group, 2020-2030 (US$ Million)

8. Leading Companies
8.1 National Institute of Allergy and Infectious Diseases
8.1.1 Company Overview
8.1.2 Product Offerings/Portfolio
8.1.3 Clinical Trial Activity
8.2 King Abdullah International Medical Research Center
8.2.1 Company Overview
8.2.2 Product Offerings/Portfolio
8.2.3 Clinical Trial Activity
8.3 CanSino Biologics Inc
8.3.1 Company Overview
8.3.2 Product Offerings/Portfolio
8.3.3 Clinical Trial Activity
8.4 Philipps University Marburg Medical Center
8.4.1 Company Overview
8.4.2 Product Offerings/Portfolio
8.4.3 Clinical Trial Activity
8.5 Naval Medical Research Center
8.5.1 Company Overview
8.5.2 Product Offerings/Portfolio
8.5.3 Clinical Trial Activity
8.6 SAB Biotherapeutics Inc
8.6.1 Company Overview
8.6.2 Product Offerings/Portfolio
8.6.3 Clinical Trial Activity
8.7 Novavax
8.7.1 Company Overview
8.7.2 Product Offerings/Portfolio
8.7.3 Clinical Trial Activity
8.8 Gilead
8.8.1 Company Overview
8.8.2 Product Offerings/Portfolio
8.8.3 Clinical Trial Activity
8.9 Inovio
8.9.1 Company Overview
8.9.2 Product Offerings/Portfolio
8.9.3 Clinical Trial Activity
8.10 Entos Pharmaceuticals, Inc
8.10.1 Company Overview
8.10.2 Product Offerings/Portfolio
8.10.3 Clinical Trial Activity

9. Conclusion

10. Glossary

LIST OF TABLES
Table 1 Country wise Outbreaks
Table 2 Global Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Region, 2020-2030 (US$ million, CAGR %, AGR %)
Table 3 Global Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million, CAGR %, AGR %)
Table 4 Global Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million, CAGR %, AGR %)
Table 5 North America: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Country, 2020-2030 (US$ million, CAGR %, AGR %)
Table 6 North America: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million, CAGR %, AGR %)
Table 7 North America: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million, CAGR %, AGR %)
Table 8 North America: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 9 U.S.: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 10 Canada: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 11 Europe: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Country, 2020-2030 (US$ million, CAGR %, AGR %)
Table 12 Europe: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million, CAGR %, AGR %)
Table 13 Europe: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million, CAGR %, AGR %)
Table 14 Europe: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 15 Germany: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 16 UK: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 17 France: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 18 Italy: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 19 Spain: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 20 Rest of Europe: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 21 Asia Pacific: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Country, 2020-2030 (US$ million, CAGR %, AGR %)
Table 22 Asia Pacific: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million, CAGR %, AGR %)
Table 23 Asia Pacific: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million, CAGR %, AGR %)
Table 24 Asia Pacific: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 25 China: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 26 Japan: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 27 India: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 28 Taiwan: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 29 South Korea: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 30 Rest of Asia Pacific: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)
Table 31 Rest of the World: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million, CAGR %, AGR %)
Table 32 Rest of the World: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million, CAGR %, AGR %)
Table 33 Rest of the World: Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million, CAGR %, AGR %)

LIST OF FIGURES
Figure 1 Global Novel Coronavirus (COVID-19) Drugs in Development Market Segmentation
Figure 2 Global Novel Coronavirus (COVID-19) Drugs in Development Market: Market Dynamics
Figure 3 Global Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million)
Figure 4 Global Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million)
Figure 5 Global Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Region, 2020, 2025 & 2030 (%)
Figure 6 North America Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million)
Figure 7 North America Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million)
Figure 8 North America Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Country, 2020, 2025 & 2030 (%)
Figure 9 U.S. Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 10 Canada Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 11 Europe Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million)
Figure 12 Europe Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million)
Figure 13 Europe Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Country, 2020, 2025 & 2030 (%)
Figure 14 Germany Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 15 UK Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 16 France Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 17 Italy Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 18 Spain Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 19 Rest of Europe Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 20 Asia Pacific Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million)
Figure 21 Asia Pacific Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million)
Figure 22 Asia Pacific Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Country, 2020, 2025 & 2030 (%)
Figure 23 Japan Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 24 China Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 25 India Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 26 Taiwan Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 27 South Korea Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 28 Rest of Asia Pacific Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast, 2020-2030 (US$ million)
Figure 29 RoW Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Drugs, 2020-2030 (US$ million)
Figure 30 RoW Novel Coronavirus (COVID-19) Drugs in Development Market Size and Forecast by Age Group, 2020-2030 (US$ million)

CanSino Biologics Inc
Entos Pharmaceuticals, Inc
Gilead
Inovio
King Abdullah International Medical Research Center
National Institute of Allergy and Infectious Diseases
Naval Medical Research Center
Novavax
Philipps University Marburg Medical Center
SAB Biotherapeutics Inc